Elotuzumab - Bristol-Myers Squibb

Drug Profile

Elotuzumab - Bristol-Myers Squibb

Alternative Names: BMS-901608; Empliciti; HuLuc63; PDL063

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD319 antigen modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 15 Dec 2017 Bristol-Myers Squibb initiates enrolment in a phase II trial in Multiple myeloma (Second-line or greater therapy, Combination therapy) in USA (IV) (NCT03361306)
  • 09 Dec 2017 Interim efficacy and adverse events data from a phase II trial in Multiple myeloma presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem 2017)
  • 05 Dec 2017 Bristol-Myers Squibb re-initiates enrolment in a phase II trial in Multiple myeloma (Second-line or greater therapy, Combination therapy) in USA and Poland based on agreement on US FDA amendments to the study protocols (IV) (NCT02612779)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top